Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Monoubiquitination of the FANCD2 protein is a key step in the Fanconi anemia (FA) tumor suppressor pathway, coinciding with this molecule's accumulation at sites of genome damage. Strong circumstantial evidence points to a requirement for the BRCA1 gene product in this step. Here, we show that the purified BRCA1/BARD1 complex, together with E1 and UbcH5a, is sufficient to reconstitute the monoubiquitination of FANCD2 in vitro. Although siRNA-mediated knockdown of BRCA1 in human cells results in defective targeting of FANCD2 to sites of DNA damage, it does not lead to a defect in FANCD2 ubiquitination. Furthermore, ablation of the RING finger domains of either BRCA1 or BARD1 in the chicken B cell line DT40 also leaves FANCD2 modification intact. Consequently, while BRCA1 affects the accumulation of FANCD2 at sites of DNA damage, BRCA1/BARD1 E3 ligase activity is not essential for the monoubiquitination of FANCD2.

Original publication

DOI

10.1016/s1097-2765(03)00281-8

Type

Journal article

Journal

Mol Cell

Publication Date

07/2003

Volume

12

Pages

247 - 254

Keywords

Animals, BRCA1 Protein, Carrier Proteins, Cell-Free System, DNA Damage, Fanconi Anemia, Fanconi Anemia Complementation Group D2 Protein, Gene Expression Regulation, Neoplastic, HeLa Cells, Humans, Iron-Binding Proteins, Ligases, Mutation, Nuclear Proteins, Protein Structure, Tertiary, RNA, Small Interfering, Tumor Suppressor Proteins, Ubiquitin, Ubiquitin-Conjugating Enzymes, Ubiquitin-Protein Ligases